LNTH Reports $377.3M Q1 Rev, $1.80 EPS, +76.5% YoY, FDA Approves PYLARIFY TruVu, Tentative PNT2003 Approval, Reaffirms 2026 Guidance
Lantheus Holdings, Inc · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · Now $97.13
+5.7% in 3d after detection
Post-detection moves
1h
—
1d
+2.3%
3d
+5.7%
7d
+2.3%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS